Metabolic and Cardiovascular Disease Research

Solution

Shanghai Model Organisms Center, Inc. (SMOC)

Our mission is editing genes and decoding life.

Our vision is to become the leader in the field of genetically modified animal models, helping people understand the life science and improving quality of life around the world.

Our values are Innovation, Dedication, Friendship and Responsibility.



INTRODUCTION

Metabolic and cardiovascular diseases are accountable for nearly 18 million deaths worldwide each year and impose an enormous burden on individuals and society.

It is critical to select appropriate animal models to accelerate the pace of drug development from laboratory research to clinical application.

Type II diabetes / High Fat Diet Induced Diabetic Mice



Fat high feed



Fat mice

Principle: Long-term feeding of high-fat diets can cause obesity and increased fasting blood glucose in mice along with fat accumulation and insulin resistance in the body to mimic human type II diabetes.


Sample requirements: C57BL/6JSmoc mice of 6-8 weeks old

Testing instruments and consumables: 60% fat high feed, Roche blood glucose meter, glucose, insulin Service cycle: 10-12 weeks

Technical indicators: Provide testing services including the testing of fasting blood glucose, body weight, GTT, and ITT as well as continuous multi-point blood collection services.

Z Type I diabetes / Ins2-C96Y(Akita-like mice)

The C96Y mutation in the Ins2 gene results in abnormal insulin processing, which leads to islet cell malfunction and death. The C57BL/6JSmoc-Ins2^{C96Y/+} mice develop severe hyperglycemia.






Fig1. The basic symptoms of ins2-C96Y mice compared with their littermate ins2^{wt/wt} controls.




Fig2. Body weight of ins2–C96Y mice compared with their littermate Ins2^{WT/WT} control. The body weight of ins2–C96Y mice was significantly lower than that of littermates.

3 Humanized GLP-1R model

Glucagon-like peptide-1 receptor (GLP-1R) is one of the most effective targets for the treatment of type 2 diabetes mellitus. We has independently developed humanized GLP-1R mouse model, which provides a powerful tool for drug screening and drug efficacy experiments.

Protein expression profile




Fig1. Analysis of hGLP1R expression by IHC.

Drug efficacy evaluation




Fig2. Hypoglycemic efficacy of the test compound in humanized GLP-1R mice.

Humanized PCSK9 mouse model

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a protease that regulates low density lipoprotein receptor (LDLR) protein levels. We created humanized PCSK9 mice that carry the human PCSK9 gene and its 3'UTR region, making them appropriate for screening antibody drugs and nucleic acid drugs.




Fig1. Impact of evolocumab treatment on CHOL and LDL-C levels in humanized PCSK9 homozygous mice.

More Models

| Cat.NO. | Model | Types | Disease Connection | Notes |
|-------------------------------|---|--|--|---|
| NM-KO-2103220 | Abcc8-KO | Knockout | MODY | |
| NM-KO-190742 | Akt2-KO | Knockout | T2DM | |
| NM-CKO-00110 | Ar-Flox | Conditional Knockout | T2DM | The expected phenotype may be observed in the above-mentioned mice that bred with Fabp4-cre mice. |
| NM-KO-190546 | | Knockout | T2DM | |
| NM-KO-191164 | Fem1b-KO | Knockout | T2DM | |
| NM-CKO-2100393 | Foxm1-Flox | Conditional Knockout | T2DM | The expected phenotype may be observed in the above-mentioned mice that bred with Pdx1-cre mice. |
| NM-CKO-200177 | Foxo1-Flox | Conditional Knockout | MODY | The expected phenotype may be observed in the above-mentioned mice that bred with ins2-cre mice. |
| NM-CKO-190062 | Hnf4a-Flox | Conditional Knockout | MODY | The expected phenotype may be observed in the above-mentioned mice that bred with ins2-cre mice. |
| NM-KI-190096 | Ins2-C96Y | Point Mutation | T1DM | |
| NM-KO-190827 | Irs1-KO | Knockout | T2DM | |
| NM-KO-00034 | Lep-KO | Knockout | T2DM | |
| NM-KO-190663 | Lepr-KO | Knockout | T2DM | |
| NM-CKO-200328 | Met-Flox | Conditional Knockout | GDM | The expected phenotype may be observed in the above-mentioned mice that bred with Pdx1-cre mice. |
| NM-KO-201323 | Phox2a-KO | Knockout | T2DM | |
| NM-CKO-210028 | Prlr-Flox | Conditional Knockout | GDM | The expected phenotype may be observed in the above-mentioned mice that bred with Pdx1-cre mice. |
| NM-CKO-200277 | Senp1-Flox | Conditional Knockout | T1DM | The expected phenotype may be observed in the above-mentioned mice that bred with Fabp4-cre mice. |
| NM-KO-191051 | Tgm2-KO | Knockout | MODY | |
| NM-KO-190565/ NR-KO-190003 | Apoe-KO(2)/ Apoe-KO(SD) | Knockout | Atherosclerosis | |
| NM-KO-18022 | Nos-KO | Knockout | Hypertensive Disease | |
| NM-HU-215004/ NR-HU-225066 | hGCGR/hGCGR(5D) | Humanization | / | Drug Discovery of Diabetes |
| NM-HU-200220 | hGLP1R | Humanization | / | Drug Discovery of Diabetes |
| NM-HU-00075 | hPCSK9 | Humanization | / | Drug Discovery of Cardiovascular Disease |
| NM-KI-18042 | Pdx1-2A-CreERT2 | Knockout | / | Cre Mice Specific for $\boldsymbol{\beta}$ Cells |
| NM-KI-225022 | Ins2-CreERT2 | Knockout | / | Cre Mice Specific for $\boldsymbol{\beta}$ Cells |
| NM-KI-200187 | Ace2-2A-CreERT2 | Knockout | / | Cre Mice Specific for Ace2 Positive Cells |
| NM-KI-200173 | Cdh5-2A-CreERT2 | Knockout | / | Cre Mice Specific for Vascular Endothelial Cells |
| NM-KI-200144/ NR-KI-210134 | Tagln-Cre/ Tagln-Cre(SD) | Knockout | / | Cre Mice Specific for Myocardial Cells |
| | - | Knockout | 1 | Cre Mice Specific for Vascular Smooth |
| NM-KI-210133 | Tek-Cre(SD) | | | Muscle Cells |
| NM-KI-210133 | Fabp4-2A-DreERT2 | Knockout | / | Muscle Cells Cre Mice Specific for Adipocytes |
| | NM-KO-2103220 NM-KO-190742 NM-CKO-00110 NM-KO-190546 NM-KO-191164 NM-CKO-2100393 NM-CKO-200177 NM-CKO-190062 NM-KI-190096 NM-KO-190827 NM-KO-190827 NM-CKO-200328 NM-CKO-200328 NM-CKO-200328 NM-CKO-200277 NM-CKO-200277 NM-CKO-190055 NM-CKO-190053 NM-CKO-200277 NM-KO-190565/ NM-KO-190053 NM-KO-190053 NM-KO-190054 NM-KO-190055 NM-KO-190053 NM-KO-190053 NM-KO-190053 NM-KO-190053 NM-KO-190053 NM-KO-190055 NM-KO-190055 NM-KO-190055 NM-KI-200173 NM-KI-200173 NM-KI-200144/ NM-KI-200144/ NM-KI-200144/ | NM-KO-2103220 Abcc8-KO NM-KO-190742 Akt2-KO NM-CKO-00110 Ar-Flox NM-KO-190546 Fem1b-KO NM-KO-191164 Fem1b-KO NM-CKO-2100393 Foxm1-Flox NM-CKO-200177 Foxo1-Flox NM-CKO-190062 Hnf4a-Flox NM-KO-190827 Irs1-KO NM-KO-190827 Irs1-KO NM-KO-19063 Lepr-KO NM-KO-200328 Met-Flox NM-CKO-200277 Senp1-Flox NM-KO-190555/ Apoe-KO(2)/ Apoe-KO(2)/ Apoe-KO(SD) NM-KO-190565/ Apoe-KO(2)/ Apoe-KO(SD) NM-KO-190055 Apoe-KO(2)/ Apoe-KO(SD) NM-KO-19005 hGCGR/hGCGR(5D) NM-KO-18022 Nos-KO NM-HU-205066 hGCGR/hGCGR(5D) NM-HU-200220 hGLP1R NM-HU-200220 hGLP1R NM-KI-18042 Pdx1-2A-CreERT2 NM-KI-200187 Cdh5-2A-CreERT2 NM-KI-200173 Cdh5-2A-CreERT2 NM-KI-200174 TagIn-Cre/ NM-KI-200144/ TagIn-Cre/ </td <td>NM-KO-2103220Abcc8-KOKnockoutNM-KO-190742Akt2-KOKnockoutNM-KO-190742Akt2-KOKnockoutNM-KO-190546KnockoutNM-KO-190546KnockoutNM-KO-191164Fem1b-KOKnockoutNM-CKO-2100393Foxm1-FloxConditional KnockoutNM-CKO-200177Foxo1-FloxConditional KnockoutNM-CKO-190062Hnf4a-FloxConditional KnockoutNM-KI-190096Ins2-C96YPoint MutationNM-KO-190827Irs1-KOKnockoutNM-KO-190827Irs1-KOKnockoutNM-KO-190828Dep-KOKnockoutNM-KO-200328Met-FloxConditional KnockoutNM-KO-200328Phox2a-KOKnockoutNM-KO-200277Senp1-FloxConditional KnockoutNM-KO-190065Apoe-KO(2)/ Apoe-KO(2)/ NR-KO-19003KnockoutNM-KO-190565/ NR-KO-18022Nos-KOKnockoutNM-KO-18022Nos-KOKnockoutNM-HU-215004/ NR-HU-20220hGLP1RHumanizationNM-KI-18042Pdx1-2A-CreERT2KnockoutNM-KI-18042Pdx1-2A-CreERT2KnockoutNM-KI-200173Cdh5-2A-CreERT2KnockoutNM-KI-200174TagIn-Cre/(SD)Knockout</td> <td>Cat.NOModelUppesConnectionNM-KO-2103220Abcc8-KOKnockoutMODYNM-KO-190742Akt2-KOKnockoutT2DMNM-KO-190742Akt2-KOKnockoutT2DMNM-CKO-00110Ar-FloxConditional KnockoutT2DMNM-KO-190546KnockoutT2DMNM-KO-191164Fem1b-KOKnockoutT2DMNM-KO-190393Foxm1-FloxConditional KnockoutT2DMNM-CKO-200177Foxo1-FloxConditional KnockoutMODYNM-CKO-190062Hnf4a-FloxConditional KnockoutT1DMNM-KO-190827Irs1-KOKnockoutT2DMNM-KO-190827Irs1-KOKnockoutT2DMNM-KO-190827Irs1-KOKnockoutT2DMNM-KO-19063Lep-KOKnockoutT2DMNM-KO-200328Met-FloxConditional KnockoutGDMNM-KO-200328PrIr-FloxConditional KnockoutGDMNM-KO-200277Senp1-FloxConditional KnockoutT1DMNM-KO-19003Apoe-KO(2)/ Apoe-KO(SD)KnockoutHUP NerescierosisNM-KO-19003Apoe-KO(SD)KnockoutHypertensive DiseaseNM-KO-19005hGCGR/hGCGR(5D)Humanization/NM-HU-215004/ NR-HU-225026hGCGR/hGCGR(5D)Humanization/NM-KI-18042Pdx1-2A-CreERT2Knockout/NM-KI-200173Cdb5-2A-CreERT2Knockout/NM-KI-200187Ace2-2A-CreERT2Knockout/</td> | NM-KO-2103220Abcc8-KOKnockoutNM-KO-190742Akt2-KOKnockoutNM-KO-190742Akt2-KOKnockoutNM-KO-190546KnockoutNM-KO-190546KnockoutNM-KO-191164Fem1b-KOKnockoutNM-CKO-2100393Foxm1-FloxConditional KnockoutNM-CKO-200177Foxo1-FloxConditional KnockoutNM-CKO-190062Hnf4a-FloxConditional KnockoutNM-KI-190096Ins2-C96YPoint MutationNM-KO-190827Irs1-KOKnockoutNM-KO-190827Irs1-KOKnockoutNM-KO-190828Dep-KOKnockoutNM-KO-200328Met-FloxConditional KnockoutNM-KO-200328Phox2a-KOKnockoutNM-KO-200277Senp1-FloxConditional KnockoutNM-KO-190065Apoe-KO(2)/ Apoe-KO(2)/ NR-KO-19003KnockoutNM-KO-190565/ NR-KO-18022Nos-KOKnockoutNM-KO-18022Nos-KOKnockoutNM-HU-215004/ NR-HU-20220hGLP1RHumanizationNM-KI-18042Pdx1-2A-CreERT2KnockoutNM-KI-18042Pdx1-2A-CreERT2KnockoutNM-KI-200173Cdh5-2A-CreERT2KnockoutNM-KI-200174TagIn-Cre/(SD)Knockout | Cat.NOModelUppesConnectionNM-KO-2103220Abcc8-KOKnockoutMODYNM-KO-190742Akt2-KOKnockoutT2DMNM-KO-190742Akt2-KOKnockoutT2DMNM-CKO-00110Ar-FloxConditional KnockoutT2DMNM-KO-190546KnockoutT2DMNM-KO-191164Fem1b-KOKnockoutT2DMNM-KO-190393Foxm1-FloxConditional KnockoutT2DMNM-CKO-200177Foxo1-FloxConditional KnockoutMODYNM-CKO-190062Hnf4a-FloxConditional KnockoutT1DMNM-KO-190827Irs1-KOKnockoutT2DMNM-KO-190827Irs1-KOKnockoutT2DMNM-KO-190827Irs1-KOKnockoutT2DMNM-KO-19063Lep-KOKnockoutT2DMNM-KO-200328Met-FloxConditional KnockoutGDMNM-KO-200328PrIr-FloxConditional KnockoutGDMNM-KO-200277Senp1-FloxConditional KnockoutT1DMNM-KO-19003Apoe-KO(2)/ Apoe-KO(SD)KnockoutHUP NerescierosisNM-KO-19003Apoe-KO(SD)KnockoutHypertensive DiseaseNM-KO-19005hGCGR/hGCGR(5D)Humanization/NM-HU-215004/ NR-HU-225026hGCGR/hGCGR(5D)Humanization/NM-KI-18042Pdx1-2A-CreERT2Knockout/NM-KI-200173Cdb5-2A-CreERT2Knockout/NM-KI-200187Ace2-2A-CreERT2Knockout/ |

*Disease Connection: It is possible that the phenotypes of above-mentioned mice are not the same as those reported models.

Metabolism and Spontaneous Activity Assay

Comprehensive Lab Animal Monitoring System

Introduction

Comprehensive Lab Animal Monitoring System (CLAMS) is a system of metabolic cages which allows for simultaneous measurement of numerous metabolic parameters. It is widely used in metabolic diseases, circadian rhythm, sleep and other studies that require continuous detection of basic metabolic indicators and daily activity.

Parameter sampling

Scales:

Simultaneous multiparameter assessment of 1 to 12 test animals. Sampling point can be accurate to 1 data point /12min.

Output parameters:

Oxygen consumption: The volume of O2 consumed in one hour per kilogram of body weight (ml/kg/hr).

Carbon dioxide production : The volume of CO2 produced in one hour per kilogram of body weight (ml/kg/hr).

Respiratory exchange ratio (RER) : CO2 Production / O2 Consumption

Heat : The amount of heat produced per hour in one kilogram of body weight (kcal/kg/hr) .


Movement in horizontal direction [XY], counts : The movement of the animal in the horizontal direction (X and Y coordinates) per hour.

Movement in vertical direction [Z], counts : The movement of the animal in the vertical direction (Z coordinate) per hour.


Food intake(g) : The amount of food consumed.

Water intake(g) : The amount of water consumed.

(A) O_2 consumption, (B) CO_2 production, (C) Respiratory Exchange Ratio (RER), (D) Heat, (E) Movement in horizontal direction [XY] and (F) Movement in vertical direction [Z] of X gene mutated mice (n=4) and their WT littermates (n=4) in Automated Metabolic and Behavioral Monitoring.



Data Presentation



Jereme G. Spiersa et al. Noninvasive assessment of altered activity following restraint in mice using an automated physiological monitoring system. Stress 2017, 20:76-84.
Karthikeyani Chellappa et al. The leptin sensitizer celastrol reduces age-associated obesity and modulates behavioral rhythms. Aging Cell 2019, 18: e12874.
Jeannette G. Lumaban et al. The Fragile X proteins Fmrp and Fxr2p cooperate to regulate glucose metabolism in mice. Human Molecular Genetics 2015, 24:2175-2184.